PTEN-induced kinase 1 (PINK1) therapy moving to next phase

Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, announced today that AbbVie, a leading global biopharmaceutical company, has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin’s lead PINK1 compound. Based on technology discovered at UCSF by Mitokinin co-founders Nicholas Hertz(Ph.D. ’13, Chem and ChemBio UCSF)and Kevan Shokat(Prof. of Chemistry UCB and Professor of Chemistry and Prof. and Co-Chair, Dept. of Cellular and Molecular Pharmacology, UCSF).3By increasing PINK1 activity, Mitokinin aims to address the mitochondrial dysfunction contributing to Parkinson’s disease pathogenesis and progression.